2 results match your criteria huabeta fibrils

  • Page 1 of 1

Amino acids variations in amyloid-beta peptides, mitochondrial dysfunction, and new therapies for Alzheimer's disease.

Hani Atamna

J Bioenerg Biomembr 2009 Oct;41(5):457-64

Department of Basic Sciences, Neuroscience, The Commonwealth Medical College, 501 Madison Avenue, Scranton, PA 18510, USA.

Soluble oligomers and/or aggregates of Amyloid-beta (Abeta) are viewed by many as the principal cause for neurodegeneration in Alzheimer's disease (AD). However, the mechanism by which Abeta and its aggregates cause neurodegeneration is not clear. The toxicity of Abeta has been attributed to its hydrophobicity. Read More

View Article and Full-Text PDF
October 2009

Characterisation of the binding of amyloid imaging tracers to rodent Abeta fibrils and rodent-human Abeta co-polymers.

Biochem Biophys Res Commun 2006 Sep 30;347(3):669-77. Epub 2006 Jun 30.

GlaxoSmithKline Research and Development, Translational Medicine and Genetics, Addenbrookes Hospital, Cambridge, UK.

Despite the application of amyloid imaging agents such as PIB, SB13, and FDDNP in Alzheimer's disease (AD) patients, the successful use of these agents in transgenic mice models of AD has not been reported to date. As a first step in understanding the behaviour of these ligands in transgenic models of AD, we have investigated in a series of in vitro ligand binding assays the interaction of selected agents, including PIB, FDDNP, SB13, and BSB, with amyloid fibrils produced from rodent Abeta(1-40) (roAbeta) peptide. The data indicate that the ligand binding affinities together with the pattern and number of binding sites on the roAbeta fibrils are broadly conserved with that reported previously for human Abeta(1-40) (huAbeta) fibrils. Read More

View Article and Full-Text PDF
September 2006
  • Page 1 of 1